

12491

CYP11A1 Antibody



Orders: 877-616-CELL (2355)

orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W, IP	Reactivity: H M R	Sensitivity: Endogenous	MW (kDa): 50	Source/Isotype: Rabbit	UniProt ID: #P05108	Entrez-Gene Id: 1583
Product Usage Information		Application Western Blotting Immunoprecipitation			Dilution 1:1000 1:50	
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA and 50% glycerol. Store at – 20°C. Do not aliquot the antibody.				
Specificity/Sensitivity		CYP11A1 Antibody recognizes endogenous levels of total CYP11A1 protein.				
Source / Purification		Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human CYP11A1 protein. Antibodies are purified by protein A and peptide affinity chromatography.				
Background		In steroidogenic tissues, such as the adrenal cortex, testis, ovary, and placenta, all steroids are synthesized from the common precursor cholesterol. Two families of steroidogenic enzymes, cytochrome P450 hydroxylase enzymes (CYP) and hydroxysteroid dehydrogenases (HSD), catalyze the production of most steroids. There are six distinct steroid hydroxylases, which are cytochrome P450 enzymes encoded by the steroidogenic <i>CYP</i> gene family (1). The cytochrome P450scc (cholesterol sidechain cleavage enzyme) encoded by <i>CYP11A1</i> catalyzes the first and rate-limiting step in steroidogenesis, conversion of cholesterol into pregnenolone (2). CYP11A1, located in the inner membrane of mitochondria, cooperates with two coenzymes, ferredoxin and ferredoxin reductase, to carry out three successive oxidation-reduction reactions of cholesterol (3-5). In the adrenal cortex, testis, and ovary, CYP11A1 expression is regulated by the cAMP-PKA pathway (6), and the transcription factor SF1/NR5A1 has been shown to play a central role in mediating the cAMP signal on the <i>CYP11A1</i> promoter within steroidogeneic cells of the adrenal cortex and gonads (7). Defects in CYP11A1 are the cause of adrenal insufficiency congenital with 46, XY sex reversal (AICSR), which is a rare disorder that can present as acute adrenal insufficiency in infancy or childhood (8,9).				
Background References		 Nelson, D.R. et al. (1993) DNA Cell Biol 12, 1-51. Richards, J.S. et al. (1987) Recent Prog Horm Res 43, 231-76. Hanukoglu, I. and Jefcoate, C.R. (1980) J Biol Chem 255, 3057-61. Hanukoglu, I. et al. (1981) J Biol Chem 256, 4329-35. Hanukoglu, I. et al. (1981) J Biol Chem 256, 4321-8. Hu, M.C. et al. (1991) Biochem J 274 (Pt 3), 813-7. Watanabe, N. et al. (1994) Eur J Biochem 222, 825-34. Tajima, T. et al. (2001) J Clin Endocrinol Metab 86, 3820-5. Katsumata, N. et al. (2002) J Clin Endocrinol Metab 87, 3808-13. 				

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween\$ 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting **IP:** Immunoprecipitation

Cross-Reactivity Key

H: Human M: Mouse R: Rat

Trademarks and Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.